Preventive PCI versus optimal medical therapy only for vulnerable plaques
Marc Bonaca, MD
APOC3 ASO significantly lowers triglycerides in patients with hypertriglyceridemia and high CV risk
Brian Bergmark, MD
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
Michael Gibson, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Om P. Ganda, MD
Loading...
We’re glad to see you’re enjoying PACE-CME…but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.